Oh, Dear, the “Ethicists” Aren’t Going to Be Happy with BusinessWeek…

From BusinessWeek Online today:
Commentary: Color-Blind Drug Research Is Myopic:

“…‘It’s imperative that we look at racially specific differences,’ says Dr. Esteban González Burchard, assistant professor at the University of California at San Francisco. ‘The one-size-fits-all approach to developing drugs is no longer valid.’ Certainly there is growing evidence that a number of drugs seem to offer different benefits — or pose different risks — depending on race. Studies have shown that hypertension drugs called ACE inhibitors are less effective in black patients than in other groups. The lung cancer drug Iressa has shown higher rates of effectiveness in Asians. And when GlaxoSmithKline PLC warned of a possible link between its asthma drug Serevent and life-threatening asthmatic episodes, the problem appeared to be more common in blacks.…”